1. Antigen-Specific Antibody Signature Is Associated with COVID-19 Outcome.
- Author
-
Salgado BB, Jordão MF, de Morais TBDN, da Silva DSS, Pereira Filho IV, Salgado Sobrinho WB, Carvalho NO, Dos Santos RO, Forato J, Barbosa PP, Toledo-Teixeira DA, Pinto KR, Correia IS, Cordeiro IB, Souza Neto JN, Assunção EN, Val FFA, Melo GC, Sampaio VS, Monteiro WM, Granja F, Souza WM, Astolfi Filho S, Proenca-Modena JL, Lalwani JDB, Lacerda MVG, Nogueira PA, and Lalwani P
- Subjects
- Humans, SARS-CoV-2, Antibodies, Viral, Immunoglobulin G, Immunoglobulin A, Immunoglobulin M, Spike Glycoprotein, Coronavirus, COVID-19
- Abstract
Numerous studies have focused on inflammation-related markers to understand COVID-19. In this study, we performed a comparative analysis of spike (S) and nucleocapsid (N) protein-specific IgA, total IgG and IgG subclass response in COVID-19 patients and compared this to their disease outcome. We observed that the SARS-CoV-2 infection elicits a robust IgA and IgG response against the N-terminal (N1) and C-terminal (N3) region of the N protein, whereas we failed to detect IgA antibodies and observed a weak IgG response against the disordered linker region (N2) in COVID-19 patients. N and S protein-specific IgG1, IgG2 and IgG3 response was significantly elevated in hospitalized patients with severe disease compared to outpatients with non-severe disease. IgA and total IgG antibody reactivity gradually increased after the first week of symptoms. Magnitude of RBD-ACE2 blocking antibodies identified in a competitive assay and neutralizing antibodies detected by PRNT assay correlated with disease severity. Generally, the IgA and total IgG response between the discharged and deceased COVID-19 patients was similar. However, significant differences in the ratio of IgG subclass antibodies were observed between discharged and deceased patients, especially towards the disordered linker region of the N protein. Overall, SARS-CoV-2 infection is linked to an elevated blood antibody response in severe patients compared to non-severe patients. Monitoring of antigen-specific serological response could be an important tool to accompany disease progression and improve outcomes.
- Published
- 2023
- Full Text
- View/download PDF